Sharps Technology Stock Soars After $400M Solana Treasury Deal
By ATTN Desk · Editorial oversight: Sean Han
Introduction
SHARPS TECHNOLOGY INC (NASDAQ: STSS) is a Melville, New York–based medical device company that designs, manufactures, and commercializes smart safety syringes. Its product lines—Sharps Provensa™, SecureGard®, and SoloGard®—are designed to eliminate accidental needlestick injuries, prevent needle reuse, and minimize vaccine or drug waste. The company’s facility is ISO-certified, FDA-cleared, and CE-marked, and its syringes comply with U.S. regulatory and World Health Organization guidelines.
Corporate Structure
According to LinkedIn and the company’s investor relations site, Sharps Technology employs between 51 and 200 staff across research and development, manufacturing, quality assurance, and commercial functions. Leadership includes CEO Robert Hayes and Executive Chairman Paul K. Danner, who oversee strategic partnerships, capital-raising, and expansion initiatives. The board and management team combine medical device and capital markets experience to support the transition from research and development to commercial operations.
Safety Syringes by Testalize.me
Developments and News
On March 6, 2025, CEO Robert Hayes issued a corporate update detailing the closing of a $20 million financing in January and debt repayment to zero, alongside milestones in Hungary manufacturing under the SoloGard and SecureGard agreements.
In mid-2025, Sharps completed its first product shipments to customers in the U.S. and Europe, marking the beginning of commercial revenue. On June 18, 2025, the company announced the second commercial delivery under a five-year, $50 million SoloGard supply agreement with a U.S. medical products partner and the initiation of facility upgrades. By mid-2025, qualification orders for SecureGard syringes commenced with Central and Eastern European healthcare networks, notably Penta Hospitals International.
On August 14, 2025, an amendment to Schedule 13G/A reported that Altium Capital Management LLC and affiliated funds held 35,659 shares (3.48% of outstanding stock), all shared voting power. Two days later, on August 16, 2025, Sharps filed a Form S-8 registering 2,000,000 shares under its 2025 Equity Incentive Plan. On August 25, 2025, the company disclosed in a Form 8-K a $400 million private placement to establish a Solana digital asset treasury strategy, involving leading digital asset institutions.
Financial and Strategic Analysis
As of August 26, 2025, STSS shares traded at $14.27, an increase of 46.66% on the day, with a volume of 1,051,904 on the NASDAQ. A snapshot of recent metrics (source: Yahoo Finance) shows:
| Metric | Value |
|---|---|
| Market Capitalization | $11.7 million |
| 52-Week Range | $3.30–$2,145.00 |
| Trailing Revenue (TTM) | $222,720 |
| Net Income (TTM) | –$723,350 |
| Total Cash (MRQ) | $8.32 million |
| Levered Free Cash Flow (TTM) | –$6.94 million |
| Price/Sales (TTM) | 8.76 |
| Price/Book (MRQ) | 0.52 |
The company’s balance sheet remains liquid following the $20 million financing, supporting ongoing capital expenditures in Hungary and planned manufacturing capacity in South Carolina. The SoloGard five-year contract for 500 million syringes has the potential to generate up to $50 million in revenue starting in the second half of 2025. SecureGard orders are in the qualification stage, with European deliveries expected to ramp in the fourth quarter of 2025. Equity incentives registered via Form S-8 aim to align employee interests with shareholder value.
Market Position and Industry Context
Global syringe demand is projected to rise amid vaccine campaigns, biologics, and injectable therapeutics. The World Health Organization forecasts a shortage of 1–2 billion units, positioning Sharps’s low-dead-space, safety-engineered syringes as a potential solution for hospitals, clinics, and immunization programs. Patented designs and regulatory approvals support the company’s competitive edge in safety, waste reduction, and usability. Expansion in Hungary provides a European manufacturing footprint, while planned U.S. capacity addresses domestic supply chain considerations.
tl;dr
On August 25, 2025, Sharps Technology announced a $400 million private placement to support a Solana digital asset treasury strategy. Shares increased by 46.66% to $14.27 on August 26, 2025. Production milestones include revenue from SoloGard under a five-year, $50 million supply agreement starting in the second half of 2025 and ongoing SecureGard qualification in Europe. Cash reserves and registered equity incentives support global capacity expansion and a transition to sustained commercial operations.